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PLINICAL RESEARCH Clinical Trials
 Randomized Trial to Evaluate the
elative Protection Against Post-Percutaneous
oronary Intervention Microvascular
ysfunction, Ischemia, and Inflammation
mong Antiplatelet and Antithrombotic Agents
he PROTECT–TIMI-30 Trial
. Michael Gibson, MS, MD,* David A. Morrow, MD, MPH,* Sabina A. Murphy, MPH,*
heresa M. Palabrica, MD,† Lisa K. Jennings, PHD,‡ Peter H. Stone, MD,* Henry H. Lui, MD,§
homas Bulle, MD, Nasser Lakkis, MD,¶ Richard Kovach, MD,# David J. Cohen, MD, MSC,**
olly Fish, BS,* Carolyn H. McCabe, BS,* Eugene Braunwald, MD,* for the TIMI Study Group
oston and Cambridge, Massachusetts; Knoxville, Jackson, and Kingsport, Tennessee; Houston, Texas;
nd Camden, New Jersey
OBJECTIVES The goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide when
administered with indirect thrombin inhibition as compared with monotherapy with direct
thrombin inhibition with bivalirudin among patients with non–ST-segment elevation acute
coronary syndromes (ACS).
BACKGROUND The optimal combination of antiplatelet and antithrombin regimens that maximizes efficacy
and minimizes bleeding among patients with non–ST-segment elevation ACS undergoing
percutaneous coronary intervention (PCI) is unclear.
METHODS A total of 857 patients with non–ST-segment elevation ACS were assigned randomly to
eptifibatide  reduced dose unfractionated heparin (n  298), eptifibatide  reduced-dose
enoxaparin (n  275), or bivalirudin monotherapy (n  284).
RESULTS Among angiographically evaluable patients (n  754), the primary end point of post-PCI
coronary flow reserve was significantly greater with bivalirudin (1.43 vs. 1.33 for pooled
eptifibatide arms, p  0.036). Thrombolysis In Myocardial Infarction (TIMI) myocardial
perfusion grade more often was normal with eptifibatide treatment compared with bivalirudin
(57.9% vs. 50.9%, p  0.048). The duration of ischemia on continuous Holter monitoring after
PCI was significantly longer among patients treated with bivalirudin (169 vs. 36 min, p 0.013).
There was no excess of TIMI major bleeding among patients treated with eptifibatide compared
with bivalirudin (0.7%, n  4 vs. 0%, p  NS), but TIMI minor bleeding was increased (2.5%
vs. 0.4%, p  0.027) as was transfusion (4.4% to 0.4%, p  0.001).
CONCLUSIONS Among moderate- to high-risk patients with ACS undergoing PCI, coronary flow reserve
was greater with bivalirudin than eptifibatide. Eptifibatide improved myocardial perfusion
and reduced the duration of post-PCI ischemia but was associated with higher minor
bleeding and transfusion rates. Ischemic events and biomarkers for myonecrosis, inflamma-
tion, and thrombin generation did not differ between agents. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.0772364–73) © 2006 by the American College of Cardiology Foundation
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eceptor inhibitors during percutaneous coronary interven
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ion (PCI) has been associated with a reduction in adverse
linical events (1–10). With the availability of more potent
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ntithrombin regimens that optimizes efficacy and mini-
izes bleeding among patients undergoing PCI is unclear.
or instance, data suggest that when used in conjunction
ith GP IIb/IIIa inhibitors, higher doses of unfractionated
eparin (UFH) are associated with no improvement in efficacy,
et bleeding events are increased (11–13). At conventional
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June 20, 2006:2364–73 The PROTECT–TIMI-30 Trialoses, low molecular weight heparin, specifically enoxaparin
Lovenox; Aventis Pharmaceuticals, Bridgewater, New Jersey),
as been associated with increased bleeding relative to heparin
uring PCI (14 –16). The relative efficacy and safety of GP
Ib/IIIa inhibition with reduced doses of UFH or enoxaparin
ersus monotherapy with a direct thrombin inhibitor (bivaliru-
in, Angiomax, The Medicines Company, Parsippany, New
ersey) is unknown among patients at moderate to high risk for
omplications with PCI.
The goal of this study was to evaluate the relative efficacy
nd safety of GP IIb/IIIa inhibition with eptifibatide when
dministered with indirect thrombin inhibition (unfraction-
ted heparin or enoxaparin) as compared with monotherapy
ith direct thrombin inhibition with bivalirudin among
atients with non–ST-segment elevation acute coronary
yndromes. We hypothesized that selective blockade of the
latelet GP IIb/IIIa receptor with an inhibitor would
roduce superior results compared with a direct thrombin
nhibitor on microvascular dysfunction, ischemia, and in-
ammation. Efficacy end points included measures of post-
CI flow, myocardial perfusion, myonecrosis, ischemia,
nflammation, thrombin generation, and clinical events.
ETHODS
atient population. The Randomized Trial to Evaluate
he Relative PROTECTion against Post-PCI Microvas-
ular Dysfunction and Post-PCI Ischemia among Anti-
latelet and Anti-Thrombotic Agents–Thrombolysis In
yocardial Infarction-30 (PROTECT–TIMI-30) was a
andomized, open label, parallel-group, international, mul-
icenter study to evaluate the angiographic and ischemic
fficacy of eptifibatide in combination with a heparin (UFH
r enoxaparin) compared with bivalirudin monotherapy
n high-risk patients with unstable angina or non–ST-
egment elevation myocardial infarction (NSTEMI) un-
ergoing PCI.
To be enrolled in the study, patients had to meet the
ollowing inclusion criteria: age 18 to 80 years of age,
ospitalized with unstable angina/NSTEMI with chest
iscomfort or an anginal equivalent at rest 10 min
Abbreviations and Acronyms
ACT  activated clotting time
CK-MB  creatine kinase-myocardial band
CTFC  corrected TIMI frame count
GP  glycoprotein
IL  interleukin
IV  intravenous
MI  myocardial infarction
NSTEMI  non–ST-segment elevation myocardial
infarction
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarction
TMPG  TIMI myocardial perfusion grade
UFH  unfractionated heparinonsistent with acute coronary syndromes, with at least one tigh-risk feature (i.e., diabetes, a positive cardiac troponin
/I or creatine kinase-myocardial band (CK-MB), ST-
egment deviation 0.5 mm, or TIMI risk score 3) who
ere anticipated to undergo PCI of a native coronary artery.
Exclusion criteria included uncontrolled hypertension
ith a systolic blood pressure 200 mm Hg or diastolic
lood pressure 110 mm Hg that was unresponsive to
reatment for 1 h; ST-segment elevation myocardial infarc-
ion (MI) within 24 h; PCI within the previous 2 weeks;
ntraventricular conduction defect, pacing, left ventricular hy-
ertrophy or any other electrocardiographic finding that could
ake continuous electrocardiographic monitoring uninterpret-
ble; cardiogenic shock; history of a bleeding diathesis or
vidence of active bleeding within 30 days; history of a
emorrhagic stroke at any time, stroke or transient ischemic
ttack of any etiology within 30 days; platelet count of
100,000/mm3; major surgery within the previous six weeks;
ny low-molecular weight heparin within the previous 12 h;
reatment with any GP IIb/IIIa in the previous 30 days or
oncurrent or anticipated treatment; concurrent treatment
ith warfarin; estimated creatinine clearance 30 ml/min;
reatment of in-stent restenosis; or anticipated or staged
CI within 48 h. Pretreatment with clopidogrel was per-
itted. The study protocol was approved by the institu-
ional review boards at all participating sites, and all eligible
atients were required to provide written informed consent.
tudy protocol. The study design is shown in Figure 1.
fter diagnostic catheterization, 857 patients were assigned
andomly in a 1:1:1 fashion to treatment with eptifibatide
FH, eptifibatide  enoxaparin, or bivalirudin during PCI
etween August 2003 and September 2004. A central
andomization system was used that involved a permuted-
lock design in which assignment was blocked by site (block
ize of 12) and stratified according to thienopyridine use6 h
efore randomization. All patients received aspirin (160–325
g) before PCI, and 300mg of clopidogrel immediately before
tenting if they had not yet received a thienopyridine on the
ay of the procedure. For patients who were being treated with
FH at the time of screening, the UFH infusion was discon-
inued for 2 h before anticipated randomization to enable the
ransition to study anti-thrombin. It was not required to
ait 2 h until randomization for patients already receiving
FH in whom the activated partial thromboplastin time
as known to be40 s or the activated clotting time (ACT)
150 s.
Study drug was administered before wire passage. Pa-
ients in the eptifibatide  UFH arm were treated with a
ouble bolus of eptifibatide (180 g/kg intravenously [IV]
ollowed 10 min later by a second 180 g/kg IV bolus) and
2 g/kg/min IV infusion for 18 to 24 h plus a reduced
ose bolus of UFH (50 U/kg) with additional protocol-
pecified boluses to achieve a target ACT of 200 to 250 s
Fig. 1). Patients in the eptifibatide  enoxaparin arm were
reated with the same regimen of eptifibatide plus 0.5 mg/kg
V of enoxaparin (17). Patients in the bivalirudin arm were
reated with a 0.75 mg/kg IV bolus and a 1.75 mg/kg/h IV
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The PROTECT–TIMI-30 Trial June 20, 2006:2364–73nfusion of bivalirudin started simultaneously with the bolus
nd discontinued after PCI (18,19) with additional 0.3
g/kg IV boluses as needed to maintain an ACT 200 s.
ivalirudin could be continued for up to 4 h after PCI at the
iscretion of the operator. Patients randomized to the
ivalirudin arm were eligible for provisional treatment with
ptifibatide as deemed necessary by the treating interven-
ionalist, for instance, for abrupt closure, no-reflow, or
ide-branch occlusion. Doses of eptifibatide and bivalirudin
ere reduced in patients with renal insufficiency: for eptifi-
atide, the maintenance infusion was reduced to 1 g/kg/
in for patients with estimated creatinine clearance 50
l/min; for bivalirudin, the infusion was reduced to 1.40
g/kg/h IV for patients with estimated creatinine clearance
60 ml/min.
Angiography was performed before and immediately after
CI. Immediately after the last balloon inflation in the
ulprit vessel, intracoronary adenosine was administered in
he culprit artery over the course of 5 s. After the adminis-
ration of adenosine, angiography was performed for the
ssessment of the primary end point. Immediately after
ompletion of the PCI, a three-lead continuously recording
olter monitor was applied for 48 h. Adjunctive antiplatelet
herapy with either ticlopidine 250 mg twice daily or
lopidogrel 75 mg daily was administered after stent im-
lantation.
nd point assessment. The primary efficacy end point was
oronary flow reserve. The primary safety end point was
IMI major bleeding. The secondary end points were:
) the normalized duration of ischemia through 24 h after
CI among those with ischemia; 2) the composite of death,
igure 1. Design of the PROTECT–TIMI-30 trial. ACT  activated
olus; PCI  percutaneous coronary intervention; UFH  unfractionaI, and occurrence of any ischemia on the Holter recording oithin 48 h after randomization; and 3) the increase in
roponin from baseline to its peak value by 24 h (6/12
ours) post-PCI based on core laboratory analysis. Other
afety end points include TIMI minor bleeding and
ransfusion.
The coronary flow reserve is a measure of the capacity of
lood flow to be augmented in response to intracoronary
IC) adenosine (hyperemic flow) and was assessed as previ-
usly described using the corrected TIMI frame count
CTFC) (20 –22). Coronary flow reserve is calculated as the
atio of the post-PCI CTFC divided by the post-adenosine
TFC. The coronary flow improvement was calculated as
he ratio of pre-PCI CTFC divided by the post-PCI
TFC. The TIMI flow grade (23), CTFC, and TIMI
yocardial perfusion grade (TMPG) (24) were assessed as
respecified as previously defined by an angiographic core
aboratory blinded to treatment assignment.
The peak increase in troponin (the increase from baseline
o the peak value by 24 h) after PCI based on core laboratory
nalysis was a prespecified secondary end point. The myo-
ecrosis markers troponin I and CK-MB, as well as the
nflammation marker C-reactive protein, were assessed
efore and at 6 to 8 h and 18 to 24 h after PCI. The other
nflammation markers, soluble CD40 ligand, interleukin
IL)-6 and prothrombin fragment F 1.2 all were assessed at
ve time points: before PCI and at 30 min, 2 h, 6 to 8 h, and
8 to 24 h after PCI.
The prespecified clinical end point was the risk of death,
I, or recurrent ischemia on Holter monitoring by 48 h or
ischarge. Post-PCI MI within 48 h after PCI was as
efined in the Appendix. A significant episode of ischemia
ing time; d/c  discontinued; IV  intravenous; IVB  intravenous
eparin.n Holter monitoring was defined as an episode that
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June 20, 2006:2364–73 The PROTECT–TIMI-30 Trialxceeded 0.1 mV of ST-segment deviation that persisted for
1 min. The duration of ischemia on post-PCI Holter
onitoring through 24 h was an additional prespecified
econdary end point.
Bleeding end points were assessed by TIMI criteria (23).
he prespecified primary safety end point was TIMI major
leeding. All clinical events (recurrent ischemia, MI, and
leeding) were adjudicated by a clinical events committee or
olter Laboratory blinded to treatment allocation. Angio-
raphic end points were assessed by the TIMI angiographic
ore laboratory.
Cardiac troponin I, CK-MB, and high sensitivity
-reactive protein were determined in a core laboratory
TIMI Biomarker Core Lab, Boston, Massachusetts) using
stablished methods (Dimension RxL and Behring II
ephelometer, respectively, Dade-Behring, Deerfield, Illi-
ois). The decision-limit for troponin I was 0.1 ng/ml based
pon our previous work with this assay. Soluble CD40
igand, prothrombin fragment 1.2, Regulated upon Activation,
ormal T-cell Expressed and Secreted (i.e., RANTES), and
L-6 were measured at an independent core laboratory (Dr.
ennings, University of Tennessee, Knoxville).
tatistical analysis. On the basis of data from the placebo
rm of the Novel Dosing Regimen of Eptifibatide in
lanned Coronary Stent Implantation Trial (ESPRIT) (8),
coronary flow reserve of 1.28 to 0.70 was anticipated in the
ivalirudin arm. On the basis of these assumptions, a sample
ize of 267 evaluable patients per treatment group would
rovide 98% power to detect a 20% increase in coronary
ow reserve with eptifibatide in the comparison of each
ptifibatide treatment group with the bivalirudin treatment
roup.
Table 1. Baseline Characteristics
Age (yrs)
Male (%)
Previous MI (%)
Previous PCI (%)
Previous coronary artery bypass surgery (%)
Previous congestive heart failure (%)
Hypertension (%)
Cigarette smoker (%)
Diabetes (%)
Dyslipidemia (%)
Creatinine clearance (ml/min/m2)
Index event (%)
Unstable angina
NSTEMI
ST-segment depression (%)
Elevated troponin I (%)
Elevated troponin I 10  ULN (%)
Elevated CK-MB (%)
Pre-PCI TMPG 0/1/2 (%)
Pre-PCI TMPG 3 (%)
CK-MB  creatine kinase-myocardial band; MI  myocardi
elevation myocardial infarction; PCI  percutaneous coronary inte
myocardial perfusion grade; ULN  upper limits of normal.The prespecified efficacy analyses were based on the
ntention to-treat principle. The primary end point (coro-
ary flow reserve) was analyzed as a randomized, intent-to-
reat basis in angiographically evaluable patients and com-
ared with the pooled eptifibatide arms with the bivalirudin
rm as prespecified in the protocol. The analysis of efficacy
nd points was prespecified to include stratification by the
uration of clopidogrel use (6 h vs. 6h) before random-
zation. All safety analyses were based on treatment re-
eived. Analyses were performed using two-sided tests at
he 0.05 level of significance. If the pooled eptifibatide
reatment comparison was significant at the specified sig-
ificance level, then each of the two eptifibatide groups were
ndividually compared with bivalirudin at the same alpha
evel as prespecified in the protocol.
For the continuous efficacy end points, the analyses were
erformed using analysis of variance models with treatment
roup as a covariate. Because the coronary flow reserve and
he biomarker data were not normally distributed, these data
ere rank transformed for the analysis. For categorical
fficacy variables, analyses were performed using logistic
egression models with treatment group as a covariate. Data
nalysis was performed independently by the TIMI Data
oordinating Center (Brigham and Women’s Hospital,
oston, Massachusetts). Three interim assessments of safety
ere conducted by an independent data and safety moni-
oring board.
ESULTS
aseline characteristics. The treatment groups were well
atched with regard to baseline characteristics, with the
tifibatide
 573)
Bivalirudin
(n  284) p Value
0  11.1 59.7  9.8 NS
66.0 68.3 NS
22.3 20.4 NS
25.0 24.3 NS
7.3 6.7 NS
4.9 6.0 NS
65.8 65.5 NS
37.5 36.3 NS
36.5 44.4 0.026
54.3 56.3 NS
0  11.1 59.7  9.8 NS
52.1 48.9 NS
47.9 51.1
30.8 27.5 NS
53.4 55.4 NS
30.7 26.4 NS
20.6 18.2 NS
43.8 44.2 NS
56.2 55.8
rction; NS  not significant; NSTEMI  non–ST-segmentEp
(n
60.
60.
al infa
rvention; TMPG  Thrombolysis In Myocardial Infarction
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The PROTECT–TIMI-30 Trial June 20, 2006:2364–73xception of a history of diabetes mellitus, which was more
ommon in the bivalirudin group (p  0.026) (Table 1).
he index event was a NSTEMI in approximately half of
he patients and unstable angina in the other half, and
T-segment deviation was present in 30% of patients.
rug-eluting stents were deployed in 79% and bare metal
tents in 24% of patients. Median peak ACT after random-
zation in the eptifibatide  UFH group was 266 s (inter-
uartile range, 238.5 to 304 s). Median peak ACT after
andomization in the bivalirudin group was 340.5 s (inter-
uartile range, 305 to 383 s). Median time from symptom
nset to randomization was 40.3 h (interquartile range, 23 h
o 71.3 h). Study drug was given in 99.0% of the eptifibatide
roup (567 of 573) and 99.3% of the bivalirudin group (282
f 284).
ngiographic outcomes. Among angiographically evalu-
ble patients (patients with an open artery at the completion
f the PCI who did not sustain abrupt closure, emergent
oronary bypass graft surgery, or thrombotic closure with
igure 2. Among angiographically evaluable patients, the median coronary
ow reserve was greater in the bivalirudin arm.
able 2. CTFC, CFI, and CFR at Various Time Points
Eptifibatide Bivalirudin p Value
FR (post-PCI CTFC/
post-adenosine CTFC)
1.33 1.43 0.036
re-PCI CTFC 32 30.6 0.86
ost-PCI CTFC 19 21 0.16
ost-adenosine CTFC 14 14 0.41
bsolute improvement in
CTFC during PCI
10 8 0.10
FI (pre-PCI CTFC/
post-PCI CTFC)
1.55 1.41 0.036
bsolute improvement in
CTFC after adenosine
4.7 6 0.12
ll values are expressed as medians. The p values are adjusted for clopidogrel
retreatment. A low CTFC indicates faster flow. A high coronary flow index indicates
ore improved flow after PCI. A high CFR indicates better flow in response to
denosine administration.
CFI  coronary flow improvement; CFR  coronary flow reserve; CTFC 
orrected TIMI frame count; PCI  percutaneous coronary intervention.
mailout to eptifibatide in whom coronary flow reserve could
e analyzed), the median coronary flow reserve was greater
n the bivalirudin arm (1.43 [n  238] vs. 1.33 [n  516],
  0.036) (Fig. 2, Table 2). Results were similar for the
omparison of bivalirudin with the eptifibatide/UFH group
median 1.30 [n 270], p 0.025) but were not significant
or the bivalirudin compared with eptifibatide/enoxaparin
roup (median 1.38 [n  246], p  0.151).
Although the improvement in the CTFC after intracoro-
ary adenosine administration trended to be greater for
ivalirudin, the absolute improvement in the CTFC from
efore to after PCI (during the intervention itself) trended
igure 3. The Thrombolysis In Myocardial Infarction myocardial perfu-
ion grade (TMPG) 3 after percutaneous coronary intervention (PCI). The
requency of TMPG 3 after PCI was significantly greater in the eptifibatide
roup compared with the bivalirudin group. The p value has been adjusted
or the pre-PCI TMPG 3 as prespecified. The univariate p  0.074.
able 3. Univariate and Multivariate Correlates of Post-PCI
MPG 3
Univariate Multivariate
Odds
Ratio p Value
Odds
Ratio p Value
re-PCI TMPG 3 6.43 0.001 6.45 0.001
ivalirudin vs. eptifibatide
treatment
1.33 0.074 1.56 0.019
rior statin use 0.69 0.013 0.58 0.020
urrent smoker 0.72 0.036 0.69 0.047
BP at admission 1.01 0.027 1.01 0.090
lopidogrel† 1.09 0.569 1.13 0.518
yslipidemia 0.73 0.041 1.05 0.841
Nonsignificant candidates on univariate analyses (p  0.2): age, gender, race,
revious congestive heart failure, previous myocardial infarction, history of angina,
revious stenosis 50%, previous PCI, previous coronary artery bypass surgery,
nown left ventricular ejection fraction 50%, hypertension requiring medical
herapy, family history of coronary artery disease, history of diabetes, type of index
vent (unstable angina or NSTEMI), ST-segment deviation, diastolic blood pressure
t admission, heart rate at admission, weight at admission, pre-PCI Thrombolysis In
yocardial Infarction flow grade, and previous use of aspirin, beta-blocker,
ngiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium chan-
el blocker, and nitrate use. †Clopidogrel forced into multivariate model; saturated
ultivariate model used—no removal for nonstated candidates.
SBP  systolic blood pressure; other abbreviations as in Table 1.
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June 20, 2006:2364–73 The PROTECT–TIMI-30 Trialo be greater for the pooled eptifibatide arms (Table 2).
ndeed, the coronary flow improvement was significantly
reater for eptifibatide (Table 2) . The final post-adenosine
TFC was identical in the two comparison groups (Table 2).
The other prespecified angiographic end point was the
MPG, which evaluates blood flow directly into and out of
he myocardium in the territory supplied by the culprit
rtery. The frequency of normal TMPG 3 after PCI was
ignificantly greater in the eptifibatide arms compared with
he bivalirudin arm (Fig. 3). Randomization to eptifibatide
vs. bivalirudin) remained independently associated with
ormal TMPG in a multivariate analysis that adjusted for
ll potential confounders identified in univariate analyses
Table 3). When the efficacy end points were analyzed using
n as treated population, the overall results were minimally
ifferent, with no major shift in results.
iomarkers. The peak increase from baseline in biomark-
rs (troponin I, CK-MB, C-reactive protein, sCD40 ligand,
rothrombin fragment 1.2, RANTES [a protein which has
een shown to be a chemoattractant for peripheral blood
onocytes], and IL-6) did not differ between treatment
trategies (Table 4). Among patients who were CK-MB
egative at baseline (n  624), an increase in peak CK-MB
bove the upper limit of normal occurred in fewer patients
able 4. Peak Post-PCI Increase in Biomarkers of Myonecrosis,
Eptifibatide
(n  573)
roponin I (ng/ml) 0.11 (0 to 1.23)
K-MB (ng/ml) 0.30 (0.20 to 2.4)
-reactive protein (mg/l) 2.55 (0.5 to 8.3)
oluble CD40 ligand (g/l) 0.12 (0.19 to 0.57
rothrombin fragment 1.2 (mmol/l) 0.51 (0.01 to 1.5)
ANTES (pg/ml) 3,238 (3,843 to 11,
L-6 (pg/ml) 1.46 (0.5 to 3.14)
K-MB  creatine kinase-myocardial band; IL  interleukin; PCI  percutaneous
nd Secreted.igure 4. Incidence and duration of ischemia on Holter monitoring after percuta
ercutaneous coronary intervention, the median duration of ischemia was significn the eptifibatide arms compared with the bivalirudin arm
16.6% vs. 25.2%, p  0.01).
ontinuous ECG or Holter monitoring. There were no
ignificant differences in the overall percentage of patients
ith an ischemic event on Holter monitoring through 24 h
fter PCI, (5.3% for eptifibatide vs. 5.7% for bivalirudin,
 0.85). The median duration of ischemia on Holter
onitoring among patients with ischemia through 24 h
fter PCI was significantly longer in the bivalirudin arm
ompared with the pooled eptifibatide arms (36 vs. 169 min,
  0.013) (Fig. 4). Results were similar for both the
omparison of eptifibatide/enoxaparin with bivalirudin (35
in, p  0.024) and eptifibatide/UFH with bivalirudin (36
in, p  0.045).
linical events. The composite of death, MI, or isch-
mia on Holter monitoring through 48 h occurred in
8.0% of the bivalirudin arm compared with 14.2% of the
ooled eptifibatide arms (odds ratio 1.35, 95% confidence
nterval 0.91 to 2.01, p  0.15), while the composite of
eath or MI occurred in 8.8% and 6.6%, respectively
odds ratio 1.37, 95% confidence interval 0.81 to 2.31, p
 0.246) (Fig. 5).
afety. The rate of TIMI major hemorrhage, the primary
afety end point, for both the eptifibatide  UFH arm and
mmation, and Thrombin Generation (Change From Baseline)
Bivalirudin
(n  284) p Value
0.21 (0 to 1.3) 0.244
0.50 (0 to 3.6) 0.084
1.90 (0.5 to 6.50) 0.177
0.12 (0.14 to 0.68) 0.660
0.41 (0 to 1.14) 0.265
2,200 (4,691 to 10,200) 0.345
1.36 (0.38 to 2.78) 0.394
ry intervention; RANTES  Regulated upon Activation, Normal T-cell ExpressedInfla
)
450)neous coronary intervention. Among patients with an ischemic event after
antly longer in the bivalirudin group compared with the eptifibatide group.
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The PROTECT–TIMI-30 Trial June 20, 2006:2364–73he bivalirudin arm was 0% (Table 5, Fig. 6). The rate of
IMI major hemorrhage in the eptifibatide  enoxaparin
rm was 1.5% (p  0.053 vs. bivalirudin). The rates of
IMI minor hemorrhage and transfusions both occurred
ignificantly more frequently in the pooled eptifibatide arms
Table 5, Fig. 7). Transfusion occurred in 0.4% of the
atients in the Bivalirudin arm, in 4.6% of patients in the
ptifibatide plus enoxaparin arms (p  0.001), and in 4.0%
f patients in the eptifibatide plus UFH arms (p  0.003).
o fatal bleeding events were observed in the study. There
ere no differences between study arms in serious adverse
vents.
ISCUSSION
he primary end point in the PROTECT–TIMI-30 trial,
oronary flow reserve, which represents the ratio of hyper-
mic to basal epicardial flow after PCI, was significantly
reater for bivalirudin among patients with a successful PCI
i.e., an open artery at completion of the PCI). Although
he incremental improvement in the CTFC after adenosine
rended to be greater for patients receiving bivalirudin, it is
otable that, in contrast, the improvement in the CTFC
chieved by the intervention itself (from pre- to post-PCI)
rended to be greater for patients treated with eptifibatide.
he final post adenosine CTFC was identical in the two
rms, indicative of equivalence in epicardial blood flow after
aximal vasodilation. Compared with bivalirudin, eptifi-
igure 5. Death (D), myocardial infarction (MI), or ischemia on Holter m
onitoring through 48 h occurred in 18% of the bivalirudin arm compa
onfidence interval [CI] 0.91 to 2.01, p  0.150), whereas the composite
.31, p  0.246). One patient in the eptifibatide arm died outside of the 48
able 5. Bleeding Events Through 48 Hours
Bivalirudin
(n  282)
Eptifibatide
(Pooled)
(n  567)
Ept
Eno
(n
IMI major hemorrhage (%) 0 0.7
IMI minor hemorrhage (%) 0.4 2.5
ransfusion (%) 0.4 4.4iv  bivalirudin; Enox  enoxaparin; Ept  eptifibatide; TIMI  Thrombolysis In Myatide significantly improved myocardial perfusion and
ignificantly reduced the duration of ischemia after PCI.
owever, these benefits came at the expense of a significant
ncrease in TIMI minor bleeding and need for transfusion.
It is notable that the CFR results and the myocardial
erfusion results are divergent. This mismatch of improved
picardial flow and reduced myocardial performance after
mbolization has been noted in prior studies (25–27). In
nimal models, microembolization has been associated with
yperemia as surrounding territories increase their release of
ndogenous adenosine (25,27). A progressive decline in left
entricular performance with each episode of embolization
as been noted despite sustained hyperemia after each
mbolic episode (25–27). Given that zones surrounding the
mbolic territory can become hyperemic while at the same
ime the injured zone has impaired perfusion, a perplexing
cenario can result: heterogeneity can exist in the velocity of
ye within a given epicardial artery. In these scenarios, some
egions of the epicardial artery are hyperemic (usually the
roximal territory), whereas other regions have slower ve-
ocity (usually the distal territory that has sustained embo-
ization). This heterogeneity in the velocity of dye is not
aptured with the use of either a Doppler velocity wire or
he corrected TIMI frame count and warrants further
nvestigation.
Although the coronary flow reserve assesses the improve-
ent in epicardial flow after adenosine administration, the
ring through 48 h. The composite event of D, MI, or ischemia on Holter
ith 14.2% of the pooled eptifibatide arms (odds ratio [OR] 1.35, 95%
r MI occurred in 8.8% and 6.6%, respectively (OR 1.37, 95% CI 0.81 to
ndow (at 3 days after randomization) secondary to a retroperitoneal bleed.
de/
rin
2)
Eptifibatide/
UFH
(n  298)
p Value
(Biv vs.
Ept Pooled)
p Value
(Biv vs.
Ept/Enox)
p Value
(Biv vs.
Ept/UFH)
0 0.308 0.053 —
3.0 0.027 0.201 0.021
4.0 0.001 0.001 0.003onito
red wifibati
xapa
 26
1.5
1.5
4.6ocardial Infarction; UFH  unfractionated heparin.
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June 20, 2006:2364–73 The PROTECT–TIMI-30 Trialost-PCI TMPG assesses the entrance and exit of dye
irectly into the muscle itself in the area supplied by the
ulprit artery (24,28). The administration of eptifibatide was
ssociated with greater rates of normal TMPG, even after
djustment for all identified confounders in a multivariate
odel. This finding builds upon several previous angio-
raphic observations in which GP IIb/IIIa inhibition has
een associated with improved myocardial perfusion.
 29 –33).
Although the incidence of post-PCI Holter ischemia did
ot differ between treatment groups, the duration of isch-
mia on the post-PCI Holter (a prespecified secondary end
oint) was significantly shorter with eptifibatide. This is
imilar to the trend that was observed in favor of abciximab
ompared with heparin in the Chimeric 7E3 Antiplatelet
herapy in Unstable Angina Refractory to Standard Treat-
ent (CAPTURE) trial (9 vs. 61 min, p  0.10) (34).
here was no difference between treatment strategies with
espect to the increase in biomarkers after PCI. The trial
opulation in the PROTECT–TIMI-30 trial included a
reater proportion of patients with elevated markers of
yonecrosis at baseline than did previous studies using
roponin or CK-MB elevations after PCI as an end point. It
s possible that any difference in the extent of necrosis after
I was masked by ongoing biomarker release from the
igure 6. Incidence of Thrombolysis In Myocardial Infarction (TIMI) m
oint, did not differ between the eptifibatide (EPT, pooled) and bivalirudigure 7. Incidence of transfusion. The rate of transfusion occurred significan
ivalirudin (BIV) treatment group. ENOX reduced-dose enoxaparin; UFH ndex event. Among patients with no CK increase at
aseline in whom an increase in CK-MB after PCI more
ikely reflects myonecrosis accompanying the PCI, it is
otable that the risk of an increase in CK-MB after PCI was
ncreased significantly less among patients treated with
ptifibatide. These findings are consistent with the potential
enefit of antiplatelet therapy at the time of the PCI procedure
nd are consistent with data demonstrating reduced myo-
ecrosis with greater platelet inhibition, as shown in the
ecent Clopidogrel Loading With Eptifibatide to Arrest the
eactivity of Platelets (CLEAR PLATELETS) study (35).
Patients in this study were not assigned randomly to a
retreatment strategy with clopidogrel but, as pre-specified,
andomization was stratified and the results were analyzed
y the duration of clopidogrel pre-treatment. The risk of
eath and MI was significantly reduced among eptifibatide
atients who were pretreated for 6 h with clopidogrel
efore PCI. Although there was no difference in the risk of
eath and MI among those patients pretreated for longer
han 6 h, these findings point to the importance of inhibi-
ion of platelet function in these patients, with the benefit of
lockade of the platelet GP IIb/IIIa receptor apparent in
atients “unprotected” by blockade of the P2Y12 receptor.
he observed benefit among patients who were not pretreated
ith clopidogrel is congruent with the results of the CLEAR
emorrhage. The rate of TIMI major hemorrhage, the primary safety end
IV) treatment groups. ENOX  reduced-dose enoxaparin.ajor htly more frequently in the eptifibatide (EPT) arms compared with the
unfractionated heparin.
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The PROTECT–TIMI-30 Trial June 20, 2006:2364–73LATELETS study, in which patients who were not pre-
reated with clopidogrel before the procedure sustained an
mprovement in platelet inhibition and a reduced the risk of
yonecrosis with the addition of eptifibatide (35).
The treatment strategies did not differ with respect to the
rimary safety end point, i.e., TIMI major bleeding. This
onfirms what was observed in the Randomized Evaluation
f PCI Linking Angiomax to Reduced Clinical Events
REPLACE)-2 study, where the rates of TIMI major
leeding were 0.9% in the GP IIb/IIIa inhibitor arm and
.6% in the bivalirudin arm (p  NS) (18). However, both
he number of TIMI minor bleeds and the number of
ransfusions were substantially and significantly higher
mong patients treated with eptifibatide. A reduced dose of
noxaparin was used in the study but did not reduce the
leeding risk of GP IIb/IIIa inhibition compared with
ivalirudin, in contrast to the results of the recently com-
leted Safety and Efficacy of Enoxaparin in Percutaneous
oronary Intervention Patients: An International Random-
zed Evaluation (STEEPLE) trial of 0.5 mg/kg or 0.75
g/kg of enoxaparin demonstrated lower rates of non-
oronary artery bypass grafting-related major or minor
leeding by 48 h after PCI and no difference in death, MI,
r urgent target vessel revascularization compared with
reatment with ACT-driven UFH. Additional information
ill be provided by the results of the ongoing Acute
atheterization and Urgent Intervention Triage Strategy
rial (ACUITY) regarding the efficacy and safety of up-
tream inhibition, but these results were not available at the
ime the manuscript was submitted.
Greater ACTs after the administration of unfractionated
eparin have been associated with greater rates of bleeding
36). In an effort to reduce the risk of bleeding, the heparin
olus in the present study was reduced as was the ACT
arget for the maintenance infusion. Despite these reduc-
ions in the unfractionated heparin dosing and despite the
act that the ACT values among bivalirudin patients was
5 s longer, bleeding among bivalirudin patients was re-
uced. The present analysis adds to the body of literature
hat demonstrates an uncoupling between the risk of bleed-
ng and ACT values with bivalirudin. In a recent study in
hich the mean ACT paralleled that reported in the
EPLACE-2 trial, no association was identified between
he ACT after bivalirudin and either efficacy or safety (37).
Bivalirudin has numerous advantages over UFH, which
nclude a lack of activation of platelets, absence of circulat-
ng inhibitors, and inhibition of clot-bound thrombin. The
apid return to normal hemostasis following bivalirudin
dministration may explain at least in part the favorable
leeding profile observed in this study as well as others (38).
tudy limitations. This trial was a mechanistic one and
as not designed with sufficient power to evaluate clinical
vents. The patients enrolled in the trial were moderate- to
igh-risk patients, and the results observed may not be
pplicable to all patients in clinical practice. Previous con-omitant medication use may have modulated the baseline
nflammatory biomarker measures.
onclusions. Compared with bivalirudin, eptifibatide was
ssociated with lower coronary flow reserve but improved
yocardial perfusion as well as a reduction in the duration
f ischemia after PCI. However, these benefits came at the
xpense of an increase in TIMI minor bleeding and trans-
usion, although not TIMI major bleeding.
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PPENDIX
or the TIMI Study Group details and investigators and a
ideo showing hyperemia despite a myocardial stain, please
ee the online version of this article.
